/
AURA
$6.88-$0.12 (-1.71%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$723.7M
103M shares
52-week range
$4.73 – $9.54
45% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Price (6 mo)
Loading chart…
Change$-7.92
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $509.0K | $0 | $0 | $0 | $1.3M | $0 | $0 |
| Gross profit | −$509.0K | $0 | $0 | $0 | −$1.3M | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — |
| R&D | $19.1M | $18.0M | $25.2M | $42.2M | $63.9M | $73.3M | $90.3M |
| Operating income | −$24.1M | −$22.2M | −$35.3M | −$60.3M | −$85.0M | −$96.1M | −$112.8M |
| EBITDA | −$23.7M | −$21.4M | −$34.4M | −$57.6M | −$75.0M | −$85.6M | −$105.0M |
| Net income | −$24.2M | −$22.2M | −$35.3M | −$58.8M | −$76.4M | −$86.9M | −$106.2M |
| Net margin | — | — | — | — | — | — | — |
| EPS (diluted) | -0.01 | -1.03 | -1.58 | -1.96 | -1.93 | -1.75 | -1.76 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $19M | $-1.59 | $-1.84–$-1.34 | 3 |
| 2027 | $8M | $-1.67 | $-1.93–$-1.40 | 3 |
| 2028 | $28M | $-1.52 | $-1.60–$-1.45 | 2 |
| 2029 | $108M | $-1.10 | $-1.10–$-1.10 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.67
Price
$6.88
Implied downside
-90%
Peer comparison
Aura Biosciences, Inc. Common Stock
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
www.aurabiosciences.com- Employees
- 113
- IPO / List date
- Oct 29, 2021
- HQ
- BOSTON, MA
Held by traders on TradeandTell
No one on the platform currently holds AURA.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 102,100 | $683.0K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded AURA yet.
